Antimicrobial resistance

Burns

Volumn 25, Issue 1, 1999, Pages 17-24

  Neely, Alice N ^a   Holder, Ian Alan ^a  

^a SHRINERS HOSPITALS FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CARBENICILLIN; CEFOPERAZONE; CEFTAZIDIME; CEFTIZOXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CHLORTETRACYCLINE; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; METICILLIN; NEOMYCIN; NYSTATIN; PIPERACILLIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; BURN INFECTION; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; REVIEW;

EID: 0033082819     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0305-4179(98)00134-X     Document Type: Article

References (90)

1. Holder I.A., Neely A.N. Fear of MRSA: potential for future disaster. Burns. 24:1998;99-103.
2. Holder I.A., Neely A.N., Vancomycin resistant enterococci. Burns, 1998, 24:389-91.
3. Millar M.R., Brown N.M., Tobin G.W., Murphy P.J., Windsor A.C.M., Speller D.C.E. Outbreak of infection with penicillin-resistant Streptococcus pneumoniae in a hospital for the elderly. J. Hosp. Infect. 27:1994;99-104.
4. Fox J. Antibiotic resistance on rise globally. ASM News. 63:1997;655.
5. Vindenes H., Bjerknes R. Microbial colonization of large wounds. Burns. 21:1995;575-579.
6. Unlisted. Agencies expand programs on resistant staph. Hosp. Infect. Control 1998;25:69-72.
7. Canadian Multicenter Study Group, Blondeau J.M., Yaschuk Y. Canadian multicenter susceptibility study, with a focus on cephalosporins, from 15 Canadian medical centers. Antimicrob Agents Chemother. 41:1997;2773-2775.
8. Archibald L., Phillips L., Monnet D., McGowan J.E. Jr., Tenover F., Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis. 24:1997;211-215.
9. Donati L., Scamazzo F., Gervasoni M., Magliano A., Stankov B., Fraschini F. Infection and antibiotic therapy in 4000 burned patients treated in Milan, Italy, between 1976 and 1988. Burns. 19:1993;345-348.
10. Tenover F.C. The best of times, the worst of times: the global challenge of antimicrobial resistance. Pharm World Sci. 17(5):1995;149-151.
11. Medeiros A.A. Editorial response: relapsing infection due to Enterobacter species: lessons of heterogeneity. Clin Infect Dis. 25:1997;341-342.
12. Troillet N., Samore M.H., Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis. 24:1997;1094-1098.
13. Itokazu G.S., Quinn J.P., Bell-Dixon C., Kahan F.M., Weinstein R.A. Antimicrobial resistance rates among aerobic Gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 23:1996;779-784.
14. Neuwirth C., Siebor E., Lopez J., Pechinot A., Kazmierczak A. Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum β-lactamase to other members of the family Enterobacteriaceae. J Clin Microbiol. 34:1996;76-79.
15. Bret L., Chanal-Claris C., Sirot D., Chaibi E.B., Labia R., Sirot J. Chromosomally encoded AmpC-type β-lactamase in a clinical isolate of Proteus mirabilis. Antimicrob Agents Chemother. 42:1998;1110-1114.
16. Pena C., Pujol M., Ardanuy C., Ricart A., Pallares R., Linares J., Ariza J., Gudiol F. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Antimicrob Agents and Chemother. 42:1998;53-58.
17. Yang Y., Bhachech N., Bradford P.A., Jett B.D., Sahm D.F., Bush K. Ceftazidine-resistant Klebsiella pneumoniae and Escherichia coli isolates producing TEM-10 and TEM-43 β-lactamases from St. Louis, Missouri. Antimicrob Agents Chemother. 42:1998;1671-1676.
18. Livermore D.M. β-lactamases in laboratory and clinical resistance. Clin Micro Rev. 8:1995;557-584.
19. Dudley M. Bacterial resistance mechanism to β-lactam antibiotics: assessment of management strategies. Pharmacother. 15(1 Pt 2):1995;9S-14S.
20. Cook N. Methicillin-resistant Staphlococcus aureus versus the burn patient. Burns. 24:1998;91-98.
21. Limaye A.P., Gautom R.K., Black D., Fritsche T.R. Rapid emergence of resistance to cefepime during treatment. Clin Infect Dis. 25:1997;339-340.
22. Kim J.H., Cho E.H., Kim K.S., Kim H.Y., Kim Y.M. Cloning and nucleotide sequence of the DNA gyrase gyrA gene from Serratia marcescens and characterization of mutations in gyrA of quinolone-resistant clinical isolates. Antimicrob Agents Chemother. 42:1998;190-193.
23. Fujimaki K., Fujii T., Aoyama H., Sato K.-I., Inoue Y., Inoue M., Mitsuhashi S. Quinolone resistance in clinical isolates of Serratia marcescens. Antimicrob Agents Chemother. 33:1989;785-787.
24. Conly J., Rennie R., Johnson J., Farah S., Hellman L. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J Infect Dis. 165:1992;761-764.
25. Powderly W.G., Kobayashi G.S., Herzig G.P., Medoff G. Amphotericin B-resistant yeast infection in severely immunocompromised patients. Am J Med. 84:1988;826-832.
26. White A., Goetz M.B. Azole-resistant Candida albicans: report of two cases of resistance to fluconazole and review. Clin Infect Dis. 19:1994;687-692.
27. Newman S.L., Flanigan T.P., Fisher A., Rinaldi M.G., Stein M., Vigilante K. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS. Clin Infect Dis. 19:1994;684-686.
28. Sterling R., Gasser R.A. Jr., Ziegler A. Emergence of resistance to amphotericin B during therapy for Candida glabrata infection in an immunocompetent host. Clin Infect Dis. 23:1996;187-188.
29. Laguna F., Rodriguez-Tudela J.L., Martinez-Suarez J.V., Polo R., Valencia E., Diaz-Guerra T.M., Dronda R., Pulido F. Patterns of fluconazole susceptibility in isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis due to Candida albicans. Clin Infect Dis. 24:1997;124-130.
30. Model A., Craig C.P. Fluconazole-resistant Candida parapsilosis fungemia in a patient with AIDS. Clin Infect Dis. 22:1996;179-180.
31. Nolte F.S., Parkinson T., Falconer D.J., Dix S., Williams J., Gilmore C., Geller R., Wingard J.R. Isolation and characterization of fluconazole, and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother. 44:1997;196-199.
32. Landman D., Saurina G., Quale J.M. Failure of all antifungal therapy for infection due to Candida albicans: a new AIDS-related problem? Clin Infect Dis. 26:1998;183-184.
33. Dube M.P., Heseltine P.N.R., Rinaldi M.G., Evans S., Zawacki B. Fungemia and colonization with nystatin-resistant Candida rugosa in a burn unit. Clin Infect Dis. 18:1994;77-82.
34. Kurtz M.B., Abruzzo G., Flattery A., Bartizal K., Marrinan J.A., Li W., Milligan J., Nollstadt K., Douglas C.M. Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect Immun. 64:1996;3244-3251.
35. Vandry W.L., Tierney A.J., Wenman W.M. Investigation of a cluster of systemic Candida albicans infections in a neonatal intensive care unit. J Infect Dis. 158:1988;1375-1379.
36. Burnie J.P., Lee W., Williams J.D., Matthews R.C., Odds F.C. Control of an outbreak of systemic Candida albicans. Br Med J. 291:1985;1092-1093.
37. Green A.R., Milling M.A.P. Infection with Acinetobacter in a burns unit. Burns. 9:1983;292-294.
38. Dziekan B., Prasad J.K., Control of an outbreak of antibiotic resistant Acinetobacter baumannii in a burn intensive care unit. Am Burn Assoc Abstr 1996, p. 164, Abstr 241.
39. Dovia A., Morris S., Saffle J., Davis B., Brinton B., Woods M., An epidemic of multiply-resistant Acinetobacter in a burn center. Am Burn Assoc Abstr 1996, p. 118, Abstr 141.
40. Sherertz R.J., Sullivan M.L. An outbreak of infections with Acinetobacter calcoaceticus in burn patients: contamination of patients' mattresses. J Infect Dis. 151:1985;252-258.
41. Edgar P., Desai M.H., Linares H., Herndon D.N., Phillips L.G., Heggers J.P., Containment of a multi-resistant Serratia marcescens outbreak. Am Burn Assoc Abstr 1996, p. 164, Abstr 242.
42. Rice L.B., Eckstein E.C., DeVente J., Shlaes D.M. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis. 23:1996;118-124.
43. Gaillot O., Maruejouls C., Abachin E., Lecuru F., Arlet G., Simonet M., Berche P. Nosocomial outbreak of Klebsiella pneumoniae producing SHV-5 extended-spectrum β-lactamase, originating from a contaminated ultrasonography coupling gel. J Clin Microbiol. 36:1998;1357-1360.
44. McManus A.T., Mason A.D., McManus W.F., Pruitt B.A. Twenty-five year review of Pseudomonas aeruginosa bacteremia in a burn center. Eur J Clin Microbiol. 4:1985;219-223.
45. Richard P., Le Floch R., Chamoux C., Pannier M., Espaze E., Richet H. Pseudomonas aeruginosa outbreak in a burn unit: role of antimicrobials in the emergence of multiply resistant strains. J Infect Dis. 170:1994;377-383.
46. Tredget E.E., Shankowsky H.A., Joffe A.M., Inkson T.I., Volpel K., Paranchych W., Kibsey P.C., Alton J.C.M., Burke J.F. Epidemiology of infections with Pseudomonas aeruginosa in burn patients; the role of hydrotherapy. Clin Infect Dis. 15:1992;941-949.
47. Walton M.A., Villarreal C., Herndon D.N., Heggers J.P. The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa. Burns. 23:1997;225-227.
48. Hsueh P.-R., Teng L.-J., Yang P.-C., Chen Y.-C., Ho S.-W., Luh K.-T. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol. 36:1998;1347-1351.
49. Levy S.B. Multidrug resistance: a sign of the times. N Engl J Med. 338:1998;1376-1378.
50. Feinman S.E. Antibiotics in animal feed: drug resistance revisited. ASM News. 64:1998;24-30.
51. Levy S.B. The challenge of antibiotic resistance. Sci Am. 278:1998;46-53.
52. Salyers A.A., Amabile-Cuevas C.F. Why are antibiotic resistance genes so resistant to elimination? Antimicrob Agents Chemother. 41:1997;2321-2325.
53. Gerding D.N., Larson T.A., Hughes R.A., Weiler M., Shanholtzer C., Peterson L.R. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother. 35:1991;1284-1290.
54. French Cooperative Pneumococcus Study Group, Bedos J.-P., Chevret S., Chastang C., Geslin P., Regnier B. Epidemiological features of and risk factors for infection by Streptococcus pneumoniae strains with diminished susceptibility to penicillin: findings of a French survey. Clin Infect Dis. 22:1996;63-72.
55. Stephenson J. Icelandic researchers are showing the way to bring down rates of antibiotic-resistant bacteria. JAMA. 275:1996;175.
56. Finnish Study Group for Antimicrobial Resistance, Seppala H., Klaukka T., Vuopio-Varkila J., Muotiala A., Helenius H., Lager K., Huovinen P. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med. 337:1997;441-446.
57. Miller Y.W., Eady E.A., Lacey R.W., Cove J.H., Joanes D.N., Cunliffe W.J. Sequential antibiotic therapy for acne promotes the carriage of resistant staphylococci on the skin of contacts. J Antimicrob Chemother. 38:1996;829-837.
58. Palzkill T. β-lactamases are changing their activity spectrums. ASM New. 64:1998;90-95.
59. Blazquez J., Baquero M.-R., Canton R., Alos I., Baquero F. Characterization of a new TEM-type β-lactamase resistant to clavulanate, sulbactam and tazobactam in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother. 37:1993;2049-2063.
60. Endtz H.P. Quinolone resistance in campylobacter isolated from man and poultry following the introduction fluoroquinolones in veterinary medicine. J Antimicrob Chemother. 27:1991;199-208.
61. McCaig L.F., Hughes J.M. Trends in antimicrobial drug prescribing among office-based physicians in the United States. JAMA. 273:1995;214-219.
62. Gonzales R., Steiner J.F., Sande M.A. Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians. JAMA. 278:1997;901-904.
63. Thomas J.K., Forrest A., Bhavnani S.M., Hyatt J.M., Cheng A., Ballow C.H., Schentag J.J. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother. 42:1998;521-527.
64. Roy J. The menace of substandard drugs. World Health Forum. 15:1994;406-407.
65. Arya S.C. Emerging antibiotic resistance in Indian communities. Clin Infect Dis. 25:1997;944-945.
66. Zuger A. Changing the focus of infectious diseases to pathogen-specific therapy. Clin Infect Dis. 25:1997;348-349.
67. Casadevall A. Crisis in infectious diseases: time for a new paradigm? Clin Infect Dis. 23:1996;790-794.
68. Williams R.J., Heymann D.L. Containment of antibiotic resistance. Science. 279:1998;1153-1154.
69. Low D.E., Scheld W.M. Strategies for stemming the tide of antimicrobial resistance. JAMA. 279:1998;394-395.
70. Kunin C.M. Editorial response: antibiotic armageddon. Clin Infect Dis. 25:1997;240-241.
71. White A.C. Jr., Atmar R.L., Wilson J., Cate T.R., Stager C.E., Greenberg S.B. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities and clinical outcomes. Clin Infect Dis. 25:1997;230-239.
72. Workshop to Prevent and Control the Emergence and Spread of Antimicrobial-Resistant Microorganisms in Hospitals, Goldmann D.A., Weinstein R.A., Wenzel R.P., Tablan O.C., Duma R.J., Gaynes R.P., Schlosser J., Martone W.J. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. JAMA. 275:1996;234-240.
73. Task Force of the General Direction for Health Planning of the Spanish Ministry of Health, Baquero R. Antibiotic resistance in Spain: what can be done? Clin Infect Dis. 23:1996;819-823.
74. Levy S.B. Editorial response: antibiotic resistance worldwide - a Spanish task force responds. Clin Infect Dis. 23:1996;824-826.
75. Unlisted. Antibiotic cycling helps hospitals cope with resistance. ASM News 1996;62:457.
76. Lister P.D., Sanders W.E. Jr., Sanders C.C. Cefepime-aztreonam: a unique double β-lactam combination for Pseudomonas aeruginosa. Antimicrob Agents Chemother. 42:1998;1610-1619.
77. Chopra I., Hodgson J., Metcalf B., Poste G. The search for antimicrobial agents effective against bacteria resistant to multiple antibiotics. Antimicrob Agents Chemother. 41:1997;497-503.
78. Unlisted. Levy outlines ploy for overcoming tetracycline resistance. ASM News 1995;61:623.
79. Chopra I., Hodgson J., Metcalf B., Poste G. New approaches to the control of infections caused by antibiotic-resistant bacteria: an industry perspective. JAMA. 275:1996;401-403.
80. McDonnell W.M., Askari F.K. Immunization. JAMA. 278:1997;2000-2007.
81. Manickan E., Karem K.L., Rouse B.T. DNA vaccines: a modern gimmick or a boon to vaccinology? Crit Rev Immunol. 17:1997;139-154.
82. Murray H.W. Cytokines as antimicrobial therapy for the T cell-deficient patient: prospects for treatment of nonviral opportunistic infections. Clin Infect Dis. 17 (Suppl 2):1993;S407-S413.
83. Dinarello C.A. Blocking interleukin-1 in sepsis. J Endotox Res. 2:1995;157-162.
84. Schindel D., Maze R., Liu Q., Williams D., Grosfeld J. Interleukin-11 improves survival and reduces bacterial translocation and bone marrow suppression in burned mice. J Pediatr Surg. 32:1997;312-315.
85. Neely A.N., Holder I.A. Use of passive immunotherapy in the treatment of experimental Pseudomonas aeruginosa infections in burns. Antibiot Chemother. 39:1987;26-40.
86. Neely A.N., Holder I.A., Larrick J.W., Chong K.T. Comparison of polyclonal immunoglobulin versus O serotype specific monoclonal antibody treatment for burned Pseudomonas aeruginosa infected mice. Serodiag Immunother Infect Dis. 4:1990;221-230.
87. Neely A.N., Holder I.A. The effect of proteolytic activity on the virulence of Candida albicans in burned mice. Infect Immun. 58:1990;1527-1531.
88. Neely A.N., Orloff M.M., Holder I.A. Disparities in efficacies of anti-LPS agents in a burned mouse model of LPS intoxication versus sepsis. J Endotox Res. 3:1996;111-117.
89. Holder I.A., Neely A.N. Combined host and specific anti-Pseudomonas directed therapy for Pseudomonas aeruginosa infections in burned mice: experimental results and theoretical considerations. J Burn Care Rehab. 10:1989;131-137.
90. Neely A.N., Holder I.A. Effect of immunoglobulin G and low dose amphotericin B on Candida albicans infection in burned mice. Antimicrob Agents Chemother. 36:1992;643-646.